Leber’s hereditary optic neuropathy

April 17, 2020April 17, 2020

GenSight Readying to Ask EMA to Approve Gene Therapy for LHON

Leber's hereditary optic neuropathy, News

GenSight Biologics announced it has finished a pre-submission meeting with the European Medicines Agency (EMA), a key step in filing a request for the approval of Lumevoq, its gene therapy for ... Read more

June 24, 2016June 24, 2016

Phase 1/2 Study of Gene Therapy to Treat LHON Showing Promise in Those with Early Disease Onset

Leber's hereditary optic neuropathy, News

GenSight Biologics released new preliminary findings from a Phase 1/2 clinical trial assessing the safety and tolerability of the company’s lead investigational gene therapy, GS010, in patients with Leber’s hereditary optic neuropathy (LHON), a maternally ... Read more